InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (21 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
21
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the full record of transactions filed by Rawcliffe Adrian, Chief Executive Officer. Director active across 2 companies, notably Adaptimmune Therapeutics PLC. In total, 22 filings have been logged. Split: 0 buy · 21 sells. Total volume traded: €336k. History available since 28 June 2021. The latest transaction was disclosed on 17 January 2025 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations22 total
30,601 shares@ US$0.58085.1% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-004605:0
12,539 shares@ US$0.58792.1% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-25-003775:0
16,115 shares0Ordinary SharesSEC:0000950170-24-097290:0
9,304 shares@ US$0.792.0% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-24-004564:0
11,945 shares@ US$0.83672.7% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-24-003742:0
2,403 shares@ US$0.780.5% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-23-097853:0
2,333 shares@ US$0.920.6% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-23-075407:0
10,057 shares@ US$1.8585.1% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-23-004379:0
13,042 shares@ US$1.74686.3% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-23-003534:0
5,073 shares@ US$1.6942.4% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-23-001088:0
2,536 shares@ US$1.96891.5% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-22-097135:0
2,562 shares@ US$1.631.2% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-22-074926:0
11,096 shares@ US$3.191813.1% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-22-005053:0
11,096 shares@ US$3.19189.2% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-22-005053
14,362 shares@ US$3.556719.0% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-22-004149:0
14,362 shares@ US$3.556713.4% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-22-004149
5,532 shares@ US$4.06425.9% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-22-001668
5,532 shares@ US$4.06428.4% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-22-001668:0
2,782 shares@ US$5.1955.2% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-21-112179:0
2,782 shares@ US$5.1953.6% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-21-112179
2,794 shares@ US$4.373.0% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-21-086385
2,794 shares@ US$4.374.3% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-21-086385:0
22 of 22 declarations
About Rawcliffe Adrian
Adrian Rawcliffe is the Chief Executive Officer at Adaptimmune Therapeutics PLC. He leads the company's operations and strategy, focusing on the development of innovative immunotherapy therapies. With significant experience in the biopharmaceutical sector, Adrian is responsible for overseeing research and development initiatives and commercial growth at Adaptimmune. His leadership is essential to position the company as a leader in the field of cell therapies.
